Missouri insurer Centene will invest up to $100m in a 10-year collaboration with Washington University School of Medicine to develop personalised treatments for obesity, breast cancer, Alzheimer’s disease and diabetes. The researchers will focus on CRISPR gene editing, immunomodulatory therapies, cellular reprogramming and cancer genomics. Any treatments resulting from the partnership will be commercialised via joint venture, the ARCH Personalized Medicine Initiative.
US insurer Centene will invest up to $100m in a 10-year collaboration with Washington University School of Medicine to develop personalised treatments for obesity, breast cancer, Alzheimer’s disease and diabetes. The researchers will focus on CRISPR gene editing, immunomodulatory therapies, cellular reprogramming and cancer genomics. Any treatments resulting from the partnership will be commercialised via joint venture, the ARCH Personalized Medicine Initiative.